U.S. Hip Replacement Market Size, Share & COVID-19 Impact Analysis, By Procedure (Total Replacement, Partial Replacement, and Revision & Hip Resurfacing), By End-user (Hospitals & Ambulatory Surgery Centers, Orthopedic Clinics, and Others), and Country Forecast, 2023-2030

The U.S. hip replacement market size was worth USD 2.06 billion in 2022 and is projected to grow at a CAGR of 5.4% during the forecast period.

The prevalence of diseases, such as osteoarthritis and rheumatoid arthritis, has been increasing significantly. Hip osteoarthritis damages the hip joint leading to hip arthroplasty or hip replacement. Therefore, the increasing prevalence of osteonecrosis, osteoarthritis, and rheumatoid arthritis has been fueling the need for these procedures.

• For instance, as per the research study published by the National Center of Biotechnology Information (NCBI) in 2021, around 1.3 million people suffered from rheumatoid arthritis in the U.S.

Moreover, elderly people are more prone to osteoarthritis and fractures. Therefore, the increasing geriatric population in the U.S. has also increased the demand for hip replacement. For instance, as per the American Joint Replacement Registry (AJRR) report 2022, the average age of total hip arthroplasty was 65.7 years.

During the COVID-19 pandemic in 2020, the U.S. hip replacement market experienced a decline. This was due to the postponement of hip joint replacement surgical procedures in 2020.

LATEST TRENDS

Focus of Market Players on New Product Launches

The burden of diseases, such as hip osteoarthritis and rheumatoid arthritis, that degrades hip joints has been increasing significantly, fueling the demand for hip arthroplasty procedures.

• For instance, as per the American Joint Replacement Registry (AJRR) report 2022, total hip arthroplasty has increased significantly over the last 10 years.

To fuel this demand, market players have increased their focus on commercialization of new advanced products. In August 2022, Exactech, Inc. launched the Logical Cup System and Spartan Stem for total hip arthroplasty. This launch aimed to deliver physicians with advanced and efficient equipment.

DRIVING FACTORS

Increasing Prevalence of Osteoarthritis has been Fueling the Demand for Hip Implants

Osteoarthritis and rheumatoid arthritis damage the hip joints and lead to severe pain. Medical professionals suggest hip arthroplasty surgeries if medications are not effective to control the pain. These procedures are also conducted in case of hip fractures. The prevalence of these diseases and cases of hip injuries have been increasing significantly.

• For instance, as per data published by the Centers for Disease Control and Prevention (CDC) in 2020, around 32.5 million adults in the U.S. suffered from osteoarthritis.

The increasing prevalence of hip joint fractures, osteoarthritis, and rheumatoid arthritis has increased the number of surgical procedures conducted in the country, thereby fueling the U.S. hip replacement market growth.

Distribution of Hip Replacement Procedures by Type in the U.S. (2012-2021)

According to the American Academy of Orthopaedic Surgeons’ registry, from 2012 to 2021, around 821,640 elective primary total hip arthroplasties were conducted. Similarly, in the same period, around 103,514 revision hip arthroplasties were performed in the U.S.

RESTRAINING FACTORS

Product Recalls and High Cost of Surgeries Limit Market Growth

The increasing prevalence of osteoarthritis has increased the demand for hip implants. However, certain risk factors associated with the procedures, such as blood clots, change in leg length, and others, limit its adoption. According to the Consumer Notice, LLC, lawsuit against hip implants claimed that the patients suffered infection, metallosis, dislocation, and other serious conditions due to the defects in the hip implants received.

Many lawsuits are filed after the patients received defective hip implants. For instance, lawsuits claimed that friction between the parts of Stryker’s ABG II hip implants released ions in the patients’ bodies, causing metallosis. The company paid around USD 1.40 billion to settle 3,500 lawsuits between 2014 and 2016.

Moreover, high cost of these procedures also limits its adoption among the population. For instance, hip replacement surgeries in the U.S. can cost between USD 31,000-45,000.

Such risk factors associated with hip replacement devices and high cost associated with the procedures hamper market growth.

SEGMENTATION

By Procedure Analysis

Based on procedure, the market is classified into total replacement, partial replacement, and revision & hip resurfacing.

The total replacement segment dominated the market in 2022. Total replacement procedures are more common in adults aged 60 and above. Therefore, the increasing geriatric population and rising prevalence of osteoarthritis among the geriatric population are responsible for the segment’s dominance.

• For instance, as per the Centers for Disease Control and Prevention (CDC), the prevalence of osteoarthritis is estimated to reach 78 million adults by 2040 in the U.S.

By End-user Analysis

On the basis of end-user, the market is segmented into hospitals & Ambulatory Surgery Centers (ASCs), orthopedic clinics, and others.

The hospitals & ambulatory surgery centers segment generated a significant U.S. hip replacement market share in 2022. The growth of the segment is due to the increased number of hip arthroplasty surgeries being conducted in hospitals and favorable reimbursement policies.

KEY INDUSTRY PLAYERS

Market players, such as Zimmer Biomet, DePuy Synthes, and Stryker, accounted for a significant market share in 2022. The strong emphasis of market players on partnerships to enhance the efficiency of their products has been fueling the companies’ growth in the market.

• For instance, in March 2022, Johnson & Johnson Services, Inc., through its subsidiary DePuy Synthes, acquired CUPTIMIZE, a hip-spine analysis tool aiming to assist surgeons in understanding issues faced by patients requiring total hip arthroplasty.  

Other players in the market, such as Conformis, Exactech Inc., and MicroPort Scientific Corporation, have been working on new technologically advanced product launches to enhance their product portfolio.

• For instance, in September 2022, Conformis announced the U.S. Food and Drug Administration (FDA) clearance for its hip implant product Actera hip system.

LIST OF KEY COMPANIES PROFILED:

• Zimmer Biomet (U.S.)


• Johnson & Johnson Services, Inc. (U.S.)


• Smith+Nephew (U.K.)


• Stryker (U.S.)


• Exactech, Inc. (U.S.)


• Conformis (U.S.)


• MicroPort Scientific Corporation (China)


• B. Braun Melsungen AG (Germany)

KEY INDUSTRY DEVELOPMENTS:

• August 2022 – Exactech Inc. successfully completed the first surgery using its products Spartan Stem and Logical Cup system for hip arthroplasty.


• July 2022 – Enovis Corporation announced the commercialization of FDA-cleared Augmented Reality Visualization and Information System (ARVIS), comprising over 200 cases in the U.S. with an aim to enhance the surgical procedures.


• August 2021 – The U.S. Food and Drug Administration (FDA) approved Zimmer Biomet’s ROSA Hip System, used for robotically-assisted total hip replacement procedures.

REPORT COVERAGE

The market report provides a detailed analysis of the market. It focuses on key aspects such as an overview of technological advancements and the prevalence of osteoarthritis in the U.S. Additionally, it includes an overview of the reimbursement scenario for the devices, new product launches, key industry developments such as mergers, partnerships, & acquisitions, and the impact of COVID-19 on the market. Besides this, the report also offers insights into the market trends and highlights key industry dynamics. In addition to the aforementioned factors, it encompasses several factors that have contributed to the growth of the market in recent years.

Report Scope & Segmentation